secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0000950170-23-004753
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Pharma Q4 NUPLAZID sales $136.5M, full-year $517.2M; PDUFA for trofinetide March 12
--------------------------------------------------------------------------------

- Net sales $517.2M in 2022, up 7% YoY; Q4 sales $136.5M, up 4% YoY.
- Net loss $216.0M for 2022 vs $167.9M in 2021; Q4 loss $41.7M ($0.26/share).
- PDUFA action date March 12, 2023 for trofinetide for Rett syndrome.
- 2023 guidance: NUPLAZID sales $520-550M; R&D $235-255M; SG&A $360-380M.
- Doug Williamson appointed EVP Head of R&D in Jan 2023; Serge Stankovic retired.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000095017023004753/0000950170-23-004753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000095017023004753/acad-20230227.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-004753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer